According to court filings, Novo Nordisk notified Hims of the patent and its alleged infringement and sent a letter on February 8, 2026, demanding that the company stop its unauthorized use of the technology
The results reviewed here need to be confirmed in a clinical population
This pattern can include skipped cycles, shorter cycles, or unpredictable bleeding, and it often overlaps with other symptoms that affect weight, such as sleep disruption and mood changes
He describes it as a novel glucagonGLP-1 dual agonist with the potential to reduce liver fat, decrease harmful visceral fat, and help preserve lean muscle mass, possibly in ways that differ from current therapies
Cht lng c c xu hng c ci thin sau gim cn: gim m xen k trong c, ci thin nhy insulin ca c, ci thin chuyn ha
Annual review of immunology , doi: 10.1146/annurev-immunol-041015-055539 (2016)